ZP4207 in rescue pen: Phase II started

Zealand began a double-blind, crossover, German Phase II trial to compare single doses of 0.1, 0.3, 0.6 and 1 mg subcutaneous ZP4207 vs. 0.5 and 1 mg subcutaneous GlucaGen glucagon in about 56 Type I...